The email arrives on a Tuesday. It is addressed from a clinical trial manager whose signature block now reads a different company name. The contract your site executed six months ago references the old entity. Your IRB approval names the old sponsor. Your eISF has the old sponsor’s SOP version. And nobody — not the CRA, not the CTM, not your PI — has a clean answer to the question your IRB coordinator is now asking: who, exactly, is the sponsor of record for this study?
That question landed at sites running Amicus Therapeutics trials the moment BioMarin completed its $4.8 billion acquisition of Amicus on April 27, 2026, and began consolidating staff at the former Amicus headquarters in New Jersey. The all-cash deal at $14.50 per share closed in weeks. The operational consequences at the site level will take considerably longer to sort out.
The Documentation Gap Nobody Planned For
Every active Amicus trial site is now running a study where at least four foundational documents — the clinical trial agreement, the IRB approval letter, the investigator brochure cover page, and the IND-holder designation — reference a corporate entity that no longer exists in its prior form. Individually, each is a manageable update. Simultaneously, across a network of rare disease sites that are already resource-constrained, they represent a coordination burden that will land squarely on coordinators who did not budget the hours and IRBs that did not budget the queue space.
The regulatory mechanics here are not ambiguous. Under 21 CFR Part 312, the IND sponsor bears legal accountability for the investigation. When a sponsor is acquired and the acquiring entity assumes IND responsibilities, the FDA expects notification and, depending on the structure of the assumption, a formal transfer of obligations. The FDA’s guidance on changes during the conduct of a clinical investigation makes clear that protocol modifications and sponsor-side changes require active notification — the IND does not automatically transfer with the stock certificate.
Sites running rare disease studies carry a disproportionate share of this burden because their patient populations are small, their coordinators are managing therapeutic complexity that general sites rarely encounter, and their IRBs — often academic medical center boards with significant review queues — do not triage sponsor name-change amendments ahead of substantive protocol reviews. A central IRB might process a sponsor substitution amendment in 10 to 14 business days under expedited review. A local IRB board at a rare disease center? Four to six weeks is realistic, and that window sits directly on top of any enrollment activity that requires up-to-date IRB approval language.
The 30-day FDA notification clock adds another constraint. When a new investigator is added to a study, the sponsor has 30 days to notify the FDA via protocol amendment. The analogous obligation around sponsor assumption of IND responsibility follows similar logic — and sites need to understand that if BioMarin has not yet submitted the formal assumption documentation, the site’s CTA and IRB approval may be referencing sponsor obligations that are currently in a legal gray zone. Any deviation, SAE, or monitoring finding that occurs during that gap will require airtight documentation of who held sponsor authority at the moment the event occurred.
What Workforce Consolidation Actually Does to Site Oversight
Here is the part that does not appear in any press release: when a sponsor consolidates staff after an acquisition, the CRAs and CTMs who knew your site go away first.
Workforce consolidation at an acquired company’s headquarters does not happen uniformly across functions. Business development and regulatory affairs often retain headcount because integration needs them. Clinical operations — the people who managed site relationships, carried the monitoring visit history, and knew which of your coordinators needs an extra day’s notice before a remote visit — frequently see the deepest cuts, or the deepest churn, because two sponsor clinical ops teams cannot both run the same portfolio. Sites in the Amicus network that had strong CRA relationships built over years of rare disease protocol complexity are now operating with counterparts who are either new to the account, transitioning out, or managing uncertainty about their own roles while simultaneously trying to manage yours.
Across the sites CliniBiz works with, sponsor-side turnover during integration windows correlates directly with two operational metrics that sponsors rarely track until they become problems: data query aging and monitoring visit gaps. Queries that would have been resolved in five to seven days when the CRA knew the site’s EDC workflow start aging past 30 days when the account is handed to someone building familiarity from scratch. Monitoring visit windows that were scheduled quarterly start slipping to five and six months because the incoming team is triaging the most visible protocol risks first and treating stable sites as banked goodwill they can defer. Six months into a post-acquisition integration, that deferral shows up as a TMF completeness problem.
For rare disease trials specifically, this matters beyond the operational inconvenience. Patient populations are thin. A single site running four to six enrolled patients in an enzyme replacement therapy study is not a site the new sponsor team can afford to lose. But site disengagement — the slow withdrawal of coordinator attention when the sponsor relationship feels unstable — happens quietly, through exactly the friction described above: unanswered queries, missed visit windows, amendments that take three weeks longer than they should because nobody is sure who to send them to anymore.
What Operators Need to Do This Week
For site teams, the immediate priority is a document audit — not a comprehensive TMF review, but a targeted check of four items: the current CTA sponsor designation, the active IRB approval sponsor identification, the investigator brochure cover page, and the IND safety reporting contact information. If any of these still reference Amicus Therapeutics as the standalone sponsor entity without a formal BioMarin assumption notice attached, your PI needs to know before the next monitoring contact — not after. File the question formally with your new sponsor contact and request written confirmation of the IND assumption date and the entity now holding sponsor obligations. Put it in the TMF.
For sponsor-side counterparts navigating the BioMarin integration, the operational directive is simpler and harder to execute simultaneously: do not let site communication go dark during the handoff window. The sites that will disengage fastest are the rare disease sites carrying the most fragile enrollment — small patient populations, complex visit schedules, coordinators who chose to work this protocol because they believed in the therapeutic area, not because it pays better than an oncology trial. A brief site communication acknowledging the acquisition, naming the new CRA contact, and committing to an updated monitoring schedule is not a legal document. It costs one hour. The cost of losing a four-patient rare disease site during the enrollment period of an already-narrow study is a timeline delay that no integration synergy number accounts for.
The due diligence that makes a $4.8 billion acquisition close on schedule and the operational diligence that keeps 47 clinical trial sites enrolled and compliant are two entirely different disciplines — and only one of them shows up in the deal announcement.
References
- FiercePharma — “BioMarin consolidates staff at Amicus HQ after closing $4.8B deal for rare disease peer”
- PR Newswire — “BioMarin Completes Acquisition of Amicus Therapeutics”
- FDA — “Changes or Modifications During the Conduct of a Clinical Investigation; Final Guidance for Industry and CDRH Staff”
- MMS Holdings — “New Investigator Updates to Clinical Study Protocol”
